- Home
- News
- canada quebec
- drug loading
Drug Loading Articles & Analysis
17 news found
Ace Therapeutics, a biotechnology company pioneering novel central nervous system (CNS) delivery solutions, today announced the release of its BBBporter™ technology platform. This innovative platform is specifically designed to overcome the primary challenge in treating brain diseases: the blood-brain barrier (BBB). By leveraging a suite of biomimetic and AI-powered technologies, ...
CD Formulation, a leading pharmaceutical contract service company, has recently unveiled groundbreaking hydrogel microneedle patch technology aiming at increase the drug loading capacity and enhance drug delivery efficiency. The new technology represents a significant advancement in the field of transdermal drug delivery. The hydrogel microneedle patch consists of a patch with tiny microneedles ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced an expanded portfolio of Polydimethylsiloxane (PDMS) products, empowering researchers with versatile and biocompatible tools for groundbreaking discoveries. Polydimethylsiloxane is an elastomeric polymer with interesting properties for biomedical applications, including ...
CD Formulation has been dedicated to pharmaceutical advancements, showcasing immense expertise in the development and optimization of micro-reservoir controlled-release drug delivery systems. These innovative systems have revolutionized the way medications are administered, enhancing patient comfort and ensuring optimal therapeutic efficacy. Transdermal drug delivery systems are very popular ...
In recent years, the field of drug delivery has experienced significant advancements in the development of innovative delivery systems such as microspheres and microneedles. These advanced systems offer unique benefits, including enhanced drug stability, sustained release, and targeted delivery. However, the successful formulation and optimization of these delivery systems pose significant ...
Microneedles have emerged as groundbreaking technology in the field of drug delivery, providing a more efficient and painless way of administering medicines. These tiny, needle-like structures are designed to penetrate the outer layer of the skin, offering a range of benefits such as enhanced drug absorption, reduced side effects, and simplified self-administration. However, ensuring the ...
BOC Sciences, a leading supplier of research chemicals and custom services, has unveiled its innovative XDC bioconjugation platform, providing a significant tool for drug delivery. The newly developed XDC bioconjugation platform offered by BOC Sciences introduces a range of advanced technologies and optimized protocols, revolutionizing the process of linking compounds to biomolecules. By ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, recently introduced a line of highly efficient mRNA Transfection Reagents with low toxicity for research applications, including the mRNA Transfection Reagent, Stem mRNA Transfection Reagent, and mRNA/gRNA Transfection Reagent. mRNA transfection is the process of introducing and expressing mRNA ...
As a reliable service provider in pharmaceutical formulation development, CD Formulation constantly expands its service range and today announces to offer a comprehensive portfolio of services for drug delivery system (DDS) research, including microneedle technology services, oral thin films technology services, microencapsulation technology services, liposome drug delivery technology services, ...
EsoCap has announced that scientists from the University of Greifswald have published important data regarding a hot-melt extrusion-based spinning process to produce pharmaceutical fibers and yarns. This spinning process is very useful in the context of EsoCap’s novel drug delivery technology, enabling targeted and long-lasting local therapy of the esophagus. The rapidly dissolving yarn is ...
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, now introduces a series of dendrons products to support drug delivery research, such as DMPA-G1-Acetylene-NHBOC, DMPA-G1-Azide-NHBoc, and DMPA-G1-Biotin-Carboxyl. They can be used in theranostics, biosensors, optics, adhesives and coatings. CD Bioparticles has expanded its product offering, and ...
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, now introduces a series of Heparins products to support drug delivery research, such as the Heparin Biotin, Heparin Amine, and Heparin Thiol. Researchers can choose Heparins by molecular weight such as 27 kDa, or by functional groups such as Biotin, Amine and Thiol. For example, Heparin Biotin ...
![[IB Tomato] (VC Portfolio) Villix, Containing the Identity of Reverse Idea and Novelty](https://d32zuqhgcrpxli.cloudfront.net/eyJidWNrZXQiOiJlZS1maWxlcyIsImtleSI6ImZpbGVzLzEyNTE1Ni9pbWFnZXMvMTI1MTU2XzBfMjAyMzAyMTUxMTQwMjgzNDM5NDg4XzQwMC5QTkciLCJlZGl0cyI6eyJyZXNpemUiOnsiZml0IjoiY29udGFpbiIsImJhY2tncm91bmQiOnsiciI6MjU1LCJnIjoyNTUsImIiOjI1NSwiYWxwaGEiOjF9LCJ3aWR0aCI6MjQwLCJoZWlnaHQiOjE0NX19fQ== "[IB Tomato] (VC Portfolio) Villix, Containing the Identity of Reverse Idea and Novelty")
[IB Tomato Reporter Lim Seong-ji] “The new drug development industry is a specialized area that is difficult for general investors and shareholders to understand, and it is difficult to deliver accurate information even when publicly available. The bad examples of some companies that have been inflated even with content are hindering the development of the Korean pharmaceutical and bio ...
Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announced that the Company has been granted a new European patent, EP3706796, to add to its growing patent portfolio. This patent covers exosomes loaded with nucleic acids or ribonuclear protein complexes. The granted claims add to Evox’s patent estate, providing further ...
Interest in bilirubin is high worldwide. This is because bilirubin has already received attention as a substance that has strong antioxidant effects and immunomodulatory effects through 30,000 papers from several decades ago. However, there were clear limitations in developing it as a new drug. This is because it is extremely hydrophobic, insoluble in water. It is Bilix that solved this problem. ...
“We will make ‘bilirubin,’ a substance with antioxidant effects that removes harmful free radicals, as a disease treatment for the first time in the world.” “Over 20,000 papers since 1987 have shown that bilirubin has a therapeutic effect on various diseases,” said Myung-Lip Kim, CEO of Bilix, a bio company developing new drugs that we met last week at the ...
QXMédical acquired the world-wide exclusive rights to the bioresorbable embolic technology developed by researchers and physicians at the University of Minnesota to fill a clinical need for resorbable and drug-loadable microspheres and hydrogels. Embolics are used by interventional radiologists and oncologists to occlude vessels for a variety of clinical indications. Current market leaders ...